Biblio
] . Class II HLA mismatch improves outcomes following haploidentical transplantation with posttransplant cyclophosphamide. Blood Adv. 2020;4(20):5311-5321.
Optimal donor for African Americans with hematologic malignancy: HLA-haploidentical relative or umbilical cord blood transplant. Biol Blood Marrow Transplant. 2020.
. Prospective phase 2 trial of ixazomib after nonmyeloablative haploidentical peripheral blood stem cell transplant. Blood Adv. 2020;4(15):3669-3676.
. The Transplant Evaluation Rating Scale predicts overall survival after allogeneic hematopoietic stem cell transplantation. Blood Adv. 2020;4(19):4812-4821.